Loading…
Prevention of cisplatin-induced delayed emesis : still unsatisfactory
The incidence of and prognostic factors in cisplatin-induced delayed emesis were evaluated in 522 naive cancer patients. They each received an intravenous combination of ondansetron and one of four different doses of dexamethasone for the prevention of acute emesis and a combination of orally admini...
Saved in:
Published in: | Supportive care in cancer 2000-05, Vol.8 (3), p.229-232 |
---|---|
Main Author: | |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | The incidence of and prognostic factors in cisplatin-induced delayed emesis were evaluated in 522 naive cancer patients. They each received an intravenous combination of ondansetron and one of four different doses of dexamethasone for the prevention of acute emesis and a combination of orally administered metoclopramide plus intramuscular dexamethasone for the prevention of delayed emesis. Despite the best prophylaxis for acute and delayed emesis, 37.4% / 57.1% of patients experienced delayed vomiting / nausea. The presence of acute vomiting / nausea was the main prognostic factor in delayed vomiting / nausea; therefore, a multifactorial analysis of the results achieved during the delayed phase adjusted for those obtained during the acute phase should be carried out in every study evaluating the efficacy of different antiemetic drugs for delayed emesis.[PUBLICATION ABSTRACT] |
---|---|
ISSN: | 0941-4355 1433-7339 |
DOI: | 10.1007/s005200050290 |